Making Medicine

@johnbstanford says it twice because it's true: High deductibles mean "insured" patients are effectively paying cash anyway. Coverage alone isn't enough anymore. Watch the full episode of the @MakingMedPod at the link in our bio

@johnbstanford warns: Only 9% of experts would start a biotech career in Europe. We are importing the policies that caused their collapse. 🇺🇸⚠️ Watch the full episode of the @MakingMedPod at the link in our bio

@johnbstanford breaks down why a @pfizer drug was 10x more expensive on TrumpRx than Mark Cuban's site. Is the new platform actually saving you money? Watch the full episode of the @MakingMedPod at the link in our bio

@jefakst of @biospace reveals to @johnbstanford why the @FDA is "not functioning." Reversals, rug pulls, and the Moderna chaos are making the industry "uninvestable". 📉 Watch the full episode of the @MakingMedPod at the link in our bio

In the newest @MakingMedPod, @johnbstanford sits down with @jefakst of @biospace to unpack FDA reversals, the Moderna mRNA flu vaccine decision, biotech investment risk, and Most Favored Nation drug pricing policy. We break down regulatory uncertainty at the @FDA, vaccine investment challenges, Alzheimer’s drug development, and the rise of psychedelics in mental health treatment. We also discuss new polling showing Americans are more concerned with overall affordability, like groceries, housing, and health insurance, than with lowering prescription drug prices. Watch the full episode on YouTube: youtu.be/fRWtrAEhWN4?si… #FDA #Biotech #DrugPricing #Pharmaceuticals #HealthcarePolicy

John Stanford explains why they want high prices: they keep half the profit. The math on your prescription doesn't add up, and it’s not an accident. It’s a business model. 📉 Watch the full episode at the link in our bio

John Stanford explains why they want high prices: they keep half the profit. The math on your prescription doesn't add up, and it’s not an accident. It’s a business model. 📉 Watch the full episode at the link in our bio

John Stanford reveals the FDA is skipping Congress to approve drugs in months, not years. Staff are revolting, claiming it breaks scientific norms. Is this necessary innovation or a safety disaster waiting to happen? ⚖️ Watch the full episode at the link in our bio.

In the newest @MakingMedPod, @johnbstanford breaks down the biggest biotech stories of 2025 -- from national security priorities and venture funding shifts to AI-driven drug development, FDA approvals, and PBM reform efforts. Full episode on YouTube: youtube.com/watch?v=oaS0RU…

Last month, @SenThomTillis joined @JohnBStanford for @MakingMedPod -- warning that foreign free-riding harms American life sciences. Give the episode a listen: buff.ly/Iy1CrJD

🎙️ NEW: Making Medicine ft. @SenThomTillis A deep dive into the IP foundations of American innovation — and how policy choices like MFN-style price controls could reshape the future of U.S. R&D. 📜 Patent eligibility reform — and why uncertainty is already stalling breakthrough science 🔐 How strong IP protections keep America ahead in the global biotech race 🌐 MFN-style price controls + the risk of importing foreign pricing models ⚖️ Regulatory clarity that investors need to back new cures 💡 What it will take to preserve U.S. leadership in life sciences Watch the full conversation → youtu.be/iw-Z_avXyb0?si…

🎙️ NEW: Making Medicine ft. @SenThomTillis This episode breaks down the policies shaping America’s innovation edge — with a spotlight on MFN-style price controls and what they could mean for U.S. R&D. 🇨🇳 China’s accelerating biotech competition 📜 Patent eligibility + its “dampening effect on innovation” 🌐 MFN and why foreign price benchmarks threaten future cures ⚖️ Regulatory certainty + investment 💡 How the U.S. stays ahead Watch the full convo → youtu.be/iw-Z_avXyb0?si… 🎧 Follow @MakingMedPod for more biotech + policy insights.

HHS, FDA, and CMS leaders announced new steps this week to simplify biosimilar approvals, potentially reducing clinical testing requirements and speeding market entry for more affordable therapies. @johnbstanford covers this and more on the latest edition of @MakingMedPod:

On a new episode of @MakingMedPod, @johnbstanford shares that biotech leaders are feeling the weight of policy uncertainty, citing that "many executives and investors said what is happening in Washington makes it very, very hard to invest."

On @MakingMedPod, @johnbstanford shares what he's hearing in Boston: fewer international students, shrinking biotech pipelines, and fears of a growing "brain drain." Biotech is hard -- America needs to show young scientists that their work and talent matter here.

ICYMI: On @MakingMedPod's FDA Approvals Corner, @johnbstanford shared recent FDA approvals, celebrating important advances for patients with rare diseases and cancer. Watch here: youtube.com/watch?v=kld5KK…

On this week's @MakingMedPod, guest @maxonwifi warns that biotech is at a crossroads: the U.S. saw its first net loss in biotech jobs in years, while China pours resources into growing its ecosystem. Watch the full episode on YouTube.

On the latest @MakingMedPod, @maxonwifi highlights the wave of actions facing drugmakers: MFN deadlines, tariff pressures, and possible executive moves involving out-licensing from China. See the full episode on YouTube.

In the newest @MakingMedPod, Patrick Jordan likens MFN drug pricing to a mismatched organ transplant -- well-intentioned, but doomed long-term. The U.S. health care system is fundamentally different from the rest of the world, so a one-size-fits-all policy doesn't work.

Many countries set drug prices using comparators. That's like pricing a 4K smart TV the same as an old-school RCA because they're both "TVs." In @MakingMedPod, @johnbstanford unpacks the realities of importing MFN pricing. See the full episode on YouTube.